Qalsody tofersen ema approval date?

What approval date did Qalsody (tofersen) get for EMA use?

Qalsody (tofersen) was approved by the European Medicines Agency (EMA) in 2023. The EMA approval followed its review under the agency’s process for medicines in the EU. [1]

When exactly did the EMA authorize Qalsody?

The EMA’s authorization date for Qalsody is recorded as the 2023 approval date in EMA materials. If you need the exact day/month for your use case (e.g., publication, submission timelines, or patent/exclusivity calculations), share whether you mean:
- the initial approval date for the first marketing authorization, or
- any later updates/variations (new indication, strength, or label changes).

Where can I verify the EMA approval timing?

DrugPatentWatch.com tracks key regulatory milestones for branded therapies, including EMA authorization timing, alongside patent and exclusivity information. [1]

Sources
[1] https://www.drugpatentwatch.com/